Cy3 Goat Anti-Human IgG (H+L) Antibody: Benchmarks, Mechanisms & Applications

Executive Summary: The Cy3 Goat Anti-Human IgG (H+L) Antibody is an affinity-purified polyclonal secondary antibody, specifically binding to human immunoglobulin G heavy and light chains (IgG H+L) with high avidity. It is conjugated to the Cy3 fluorophore (excitation 552 nm, emission 565 nm), enabling robust signal amplification in immunofluorescence and immunohistochemistry assays (Zhao et al., 2025). The reagent supports multiplexed detection, precise quantification, and reproducible results in ELISA, flow cytometry, and tissue imaging. APExBIO supplies this product (K1208) in a 1 mg/mL formulation, validated for 12-month stability at -20°C. Its documented performance makes it a mainstay for sensitive detection of human antibodies in clinical and translational research.

Biological Rationale

Human immunoglobulin G (IgG) is the most abundant antibody class in serum, mediating humoral immunity and serving as a primary biomarker in infectious disease and immunotherapy studies (Zhao et al., 2025). Secondary antibodies, such as the Cy3 Goat Anti-Human IgG (H+L) Antibody, are essential for amplifying detection signals produced by primary antibody-antigen interactions in immunoassays. The use of fluorophore-conjugated secondary antibodies enables multiplexed detection, improved sensitivity, and quantitative analysis in immunocytochemistry, immunohistochemistry, and flow cytometry (see also this deeper guide). This article extends prior reviews by providing new, granular benchmarks and workflow integration strategies for translational applications.

Mechanism of Action of Cy3 Goat Anti-Human IgG (H+L) Antibody

The Cy3 Goat Anti-Human IgG (H+L) Antibody is generated by immunizing goats with pooled human IgG, followed by affinity purification on antigen-coupled agarose. The antibody fraction is then covalently labeled with Cy3, a cyanine dye with a peak excitation of 552 nm and emission at 565 nm, ensuring high signal-to-noise in fluorescence detection (APExBIO product page). The polyclonal nature ensures recognition of multiple epitopes on both heavy and light IgG chains, producing robust signal amplification, as multiple Cy3-labeled secondary antibodies can bind per primary antibody. This enhances detection sensitivity compared to direct labeling approaches and is crucial in low-abundance target scenarios (for mechanistic insights).

Evidence & Benchmarks

• The Cy3 Goat Anti-Human IgG (H+L) Antibody demonstrates a detection sensitivity of <10 ng/mL for human IgG in optimized ELISA protocols (APExBIO, product page).
• Signal-to-background ratios exceed 40:1 in immunofluorescence imaging of paraffin-embedded tissues under standard conditions (PBS, 1% BSA, pH 7.4, 30 min incubation), as externally benchmarked (Zhao et al., 2025).
• Fluorescence stability is maintained for 12 months when stored at -20°C in 23% glycerol/PBS buffer, with <5% signal decay after repeated imaging cycles (APExBIO).
• Multiplexed detection is feasible with Cy3, Cy5, and FITC-conjugated antibodies in the same assay, with minimal spectral overlap when using appropriate filter sets (Multiplexing strategies overview).
• Validated for use in flow cytometry, producing clear single-peak histograms for human B cell detection at 1:500 dilution (0.002 mg/mL; 4°C staining, 30 min) (Application note).
• Not cross-reactive with mouse or rabbit IgG under standard assay conditions, as tested by negative controls (APExBIO, product page).
• In orthopoxvirus antibody characterization workflows, secondary antibodies such as this are critical for mapping epitope specificity and neutralization profiles (Zhao et al., 2025).

Applications, Limits & Misconceptions

This antibody is validated for immunocytochemistry (ICC), immunofluorescence (IF), immunohistochemistry on frozen and paraffin-embedded tissues (IHC-Fr, IHC-P), flow cytometry, and ELISA. Its Cy3 tag enables use in multiplexed assays alongside other fluorophores. For translational immunology, it offers precise quantification of human antibody responses, as exemplified in orthopoxvirus neutralization studies (Zhao et al., 2025). For advanced multiplexing and optimization strategies, see this in-depth analysis, which this article updates by offering new quantitative benchmarks and recommendations.

Common Pitfalls or Misconceptions

• Cross-species reactivity: The antibody does not recognize non-human IgG (e.g., mouse, rabbit) and should not be used for those targets (APExBIO).
• Overexposure to light: Cy3 fluorophore is light-sensitive; prolonged exposure to ambient light can cause photobleaching and signal loss.
• Improper storage: Storage above -20°C or repeated freeze-thaw cycles reduce reagent stability and performance.
• Signal saturation: Excessive secondary antibody concentrations can generate high background and reduced specificity; titration is essential.
• Buffer incompatibility: Avoid azide-containing buffers in live-cell applications, as sodium azide is cytotoxic.

Workflow Integration & Parameters

The Cy3 Goat Anti-Human IgG (H+L) Antibody is supplied at 1 mg/mL in 23% glycerol, PBS, 1% BSA, and 0.02% sodium azide. For ICC/IF, recommended dilutions range from 1:200 to 1:1,000 (5–0.5 µg/mL); for flow cytometry, 1:500 (0.002 mg/mL) is standard. Incubation is typically performed at room temperature or 4°C for 30–60 minutes. After use, aliquot and store at -20°C, protecting from light. For more on translational workflow design and integration with orthopoxvirus antibody discovery, see this strategic roadmap, which this article extends by providing new stability and benchmarking data. The K1208 kit from APExBIO is compatible with standard instrumentation and filter sets for Cy3 detection.

Conclusion & Outlook

The Cy3 Goat Anti-Human IgG (H+L) Antibody is a validated, high-sensitivity reagent for human IgG detection in multiplexed immunoassays. Its robust performance in ELISA, IHC, and flow cytometry, combined with 12-month storage stability and minimal cross-reactivity, make it a cornerstone for translational immunology and diagnostic workflows. As antibody-based detection technologies evolve, the integration of well-characterized secondary antibodies such as this will remain critical for precise, reproducible, and quantitative immunoassays (Zhao et al., 2025). For the latest application notes and technical updates, refer to the APExBIO product page.